SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SAN DIEGO, Feb. 27, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced that Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio’s large-scale immunotherapy screening platform, MuScreen™. The webinar is scheduled for Thursday, March 1, 2018 at 11am EST (5pm CEST).
CrownBio recently completed a comprehensive immunoprofiling study to fast-track the in vivo screening of a panel of 12 commonly used syngeneic models against PD-1/PD-L1 blockade. The analysis of this large study, using both efficacy and immunophenotyping (by flow cytometry on tumor infiltrating immune cells), was conducted for both baseline and pharmacodynamic readouts. The results help address numerous scientific/technical challenges, including a multitude of characteristics for individual syngeneic models and the variations associated with studies using syngeneic models. Attendees will discover how to design and utilize a large-scale, staggered syngeneic platform to address key immuno-oncology questions, improve efficiency and reproducibility of immunotherapy development, all while reducing costs.
“CrownBio strives to provide scientists with predictive solutions that surpass traditional approaches and provide decision making during drug development,” said Dr. Henry Li, CrownBio’s Sr. Vice President of Scientific Research and Innovation. “I am looking forward to presenting conclusive data that shows the utility of our MuScreen platform to accelerate development of immunotherapeutic agents efficiently and cost-effectively.”
Learn more about CrownBio’s large-scale immunotherapy screening platform and sign up to attend the webinar here.
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
